RE: Share PriceEasy great post as always but... from your last post
The only thing left is design of Phase 3, approval of Phase 3 design, and finally financing for Phase 3.
Just to clarify... there is no more approval for the phase III trial design unless you were referring to internal SCT approval with the new CEO. At the EOP2 meeting they told the FDA the what they have and what they are planning.... the FDA gave them their input and said this is what we need and expect. We don't need to meet with the FDA again until we are in the middle or near the end of the pivotal trials.